Products - Cervical cancer | Topic | NICE

Showing 3 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Suspected Cancer: recognition and referral (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
25 March 2026
Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment [ID3753]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
25 June 2026
ID6610 Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (review of TA901)
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
26 August 2026